Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study
Eur Urol. 2026 Jan;89(1):71-79.
https://pubmed.ncbi.nlm.nih.gov/41130825/
An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC)
Radiother Oncol. 2026 Jan;214:111227.
https://pubmed.ncbi.nlm.nih.gov/41138857/
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial
Radiother Oncol. 2026 Jan;214:111202.
https://pubmed.ncbi.nlm.nih.gov/41173355/
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Lancet Oncol. 2026 Jan;27(1):45-56.
https://pubmed.ncbi.nlm.nih.gov/41449147/
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
Lancet Oncol. 2026 Jan;27(1):23-35.
https://pubmed.ncbi.nlm.nih.gov/41449145/
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results
Int J Radiat Oncol Biol Phys. 2026 Jan 1;124(1):133-146.
https://pubmed.ncbi.nlm.nih.gov/40780546/
Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial
Int J Radiat Oncol Biol Phys. 2026 Jan 1;124(1):109-121.
https://pubmed.ncbi.nlm.nih.gov/40752655/
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
Lancet. 2026 Jan 24;407(10526):363-374.
https://pubmed.ncbi.nlm.nih.gov/41448222/
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Lancet. 2026 Jan 10;407(10524):174-184.
https://pubmed.ncbi.nlm.nih.gov/41391462/
PDF
Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC
Radiother Oncol. 2026 Feb;215:111323.
https://pubmed.ncbi.nlm.nih.gov/41389860/
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
J Clin Oncol. 2026 Feb;44(4):274-285.
https://pubmed.ncbi.nlm.nih.gov/41397208/
Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study
Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):278-293.
https://pubmed.ncbi.nlm.nih.gov/41033612/
O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial
Lancet Oncol. 2026 Feb;27(2):169-180.
https://pubmed.ncbi.nlm.nih.gov/41429128/
Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):349-358.
https://pubmed.ncbi.nlm.nih.gov/40876576/
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial
Eur Urol. 2026 Mar;89(3):199-203.
https://pubmed.ncbi.nlm.nih.gov/41494929/
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial
J Clin Oncol. 2026 Mar;44(7):534-539.
https://pubmed.ncbi.nlm.nih.gov/41512219/
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
J Clin Oncol. 2026 Mar;44(7):586-597.
https://pubmed.ncbi.nlm.nih.gov/41337691/
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005
J Clin Oncol. 2026 Mar 10;44(8):630-640.
https://pubmed.ncbi.nlm.nih.gov/41529214/
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
Lancet Oncol. 2026 Mar;27(3):293-301.
https://pubmed.ncbi.nlm.nih.gov/41655576/
Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's Disease: Three-Year Secondary Analysis Data From the Prevention Group of the International Dupuytren's Evaluation of Preventative or Adjuvant Radiation Therapy (DEPART) Randomized Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 1;124(3):604-613.
https://pubmed.ncbi.nlm.nih.gov/41027544/
Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):928-936
https://pubmed.ncbi.nlm.nih.gov/41106690/
Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):1024-1032.
https://pubmed.ncbi.nlm.nih.gov/41161645/
Effectiveness of Low-Cost Polyurethane Film in Reducing Dermatitis Severity in Breast Cancer Patients With Higher Fitzpatrick Skin Types Undergoing Hypofractionated Irradiation With Simultaneous Integrated Boost: An Intrapatient Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):952-960.
https://pubmed.ncbi.nlm.nih.gov/41187861/
Simultaneous Integrated Dose Reduction Radiation Therapy Versus Conventional Fractionated Radiation Therapy With Chemotherapy for Limited-Stage Small Cell Lung Cancer in the Modern Treatment Era: A Phase 3, Randomized Clinical Trial (SDR-RT trial)
Int J Radiat Oncol Biol Phys. 2026 Mar 1;124(3):692-701.
https://pubmed.ncbi.nlm.nih.gov/41101556/
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
Lancet. 2026 Mar 7;407(10532):976-987.
https://pubmed.ncbi.nlm.nih.gov/41794436/
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial
Lancet. 2026 Mar 28;407(10535):1259-1275.
https://pubmed.ncbi.nlm.nih.gov/41875914/
PDF
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data
Radiother Oncol. 2026 Apr;217:111388.
https://pubmed.ncbi.nlm.nih.gov/41580147/
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial
J Clin Oncol. 2026 Apr 10;44(11):970-980.
https://pubmed.ncbi.nlm.nih.gov/41712876/
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
N Engl J Med. 2026 Apr 2;394(13):1257-1269.
https://pubmed.ncbi.nlm.nih.gov/41707170/
Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial
Radiother Oncol. 2026 May;218:111334.
https://pubmed.ncbi.nlm.nih.gov/41412437/
Dosimetric Comparison of Magnetic Resonance Imaging Guided Versus Reduced Margin Computed Tomography Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Post Hoc Analysis of a Phase 3 Trial
Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):266-274.
https://pubmed.ncbi.nlm.nih.gov/40482729/
Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B Study
Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):250-256.
https://pubmed.ncbi.nlm.nih.gov/39862896/
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin
Radiother Oncol. 2026 Jun;219:111479.
https://pubmed.ncbi.nlm.nih.gov/41903611/
Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT
Radiother Oncol. 2026 Jun;219:111490.
https://pubmed.ncbi.nlm.nih.gov/41905637/
Effects of rhuGM-CSF on prevention and treatment of oral mucositis in patients receiving radiotherapy for head and neck cancer: A randomized controlled trial
Radiother Oncol. 2026 Jun;219:111527.
https://pubmed.ncbi.nlm.nih.gov/41966279/
Therapeutic effect of Photobiomodulation therapy on radiation-induced oral mucositis in head and neck Cancer: A prospective double-blind, self-controlled clinical trial
Radiother Oncol. 2026 Jun;219:111495.
https://pubmed.ncbi.nlm.nih.gov/41864516/
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
Lancet Oncol. 2026 Jun;27(6):673-685.
https://pubmed.ncbi.nlm.nih.gov/42225101/
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Lancet Oncol. 2026 Jun;27(6):686-698.
https://pubmed.ncbi.nlm.nih.gov/42134381/
CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2026 Jun 1;125(2):489-501.
https://pubmed.ncbi.nlm.nih.gov/41352689/
Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial
Int J Radiat Oncol Biol Phys. 2026 Jun 1;125(2):387-398.
https://pubmed.ncbi.nlm.nih.gov/41711624/
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer
J Clin Oncol. 2026 Jul;44(19):1812-1821.
https://pubmed.ncbi.nlm.nih.gov/42166701/
Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer
Lancet Oncol. 2026 Jul;27(7):817-829
https://pubmed.ncbi.nlm.nih.gov/42372743/
Diffusion weighted MRI-based hypoxic fraction as a prognostic factor in the FLAME trial prostate cancer cohort
Radiother Oncol. 2026 Jul;220:111578.
https://pubmed.ncbi.nlm.nih.gov/42114601/
Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study
Radiother Oncol. 2026 Jul;220:111547.
https://pubmed.ncbi.nlm.nih.gov/42067068/
Impact of ultrahypofractionated adjuvant regional nodal radiotherapy on patient-reported quality of life: the HYPORT adjuvant trial (NCT03788213)
Radiother Oncol. 2026 Jul;220:111576.
https://pubmed.ncbi.nlm.nih.gov/42142535/
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial
Radiother Oncol. 2026 Jul;220:111533.
https://pubmed.ncbi.nlm.nih.gov/42140755/
Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial
J Clin Oncol. 2026 Jul;44(19):1798-1811.
https://pubmed.ncbi.nlm.nih.gov/42114027/
Acute and long-term toxicity profiles and final oncologic outcomes in the phase III ARTFORCE trial
Radiother Oncol. 2026 Aug;221:111572.
https://pubmed.ncbi.nlm.nih.gov/42119642/
Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial
Lancet Oncol. 2026 Aug;27(8):1004-1019.
https://pubmed.ncbi.nlm.nih.gov/42508427/
Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy induced nausea and vomiting (RINV): CTRI/2022/01/039723
Radiother Oncol. 2026 Aug;221:111571.
https://pubmed.ncbi.nlm.nih.gov/42119640/
Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633)
Radiother Oncol. 2026 Aug;221:111598.
https://pubmed.ncbi.nlm.nih.gov/42134662/
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
N Engl J Med. 2026 Aug 6;395(6):546-560.
https://pubmed.ncbi.nlm.nih.gov/42223077/
Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848
J Clin Oncol. 2026 Aug 20;44(24):2316-2328.
https://pubmed.ncbi.nlm.nih.gov/42456089/
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
J Clin Oncol. 2026 Aug 20;44(24):2278-2289.
https://pubmed.ncbi.nlm.nih.gov/42492022/
Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial
Lancet Oncol. 2026 Aug;27(8):959-972.
https://pubmed.ncbi.nlm.nih.gov/42508432/
Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial
J Clin Oncol. 2026 Sep;44(25):2371-2378.
https://pubmed.ncbi.nlm.nih.gov/42507974/
Quality of life and cost-effectiveness of preoperative accelerated versus postoperative conventional radiotherapy for oral cavity cancer: Results from the randomised ARTSCAN 2 trial
Radiother Oncol. 2026 Sep;222:111688.
https://pubmed.ncbi.nlm.nih.gov/42431267/
High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial
Lancet Oncol. 2026 Sep;27(9):1158-1167.
https://pubmed.ncbi.nlm.nih.gov/42636837/
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial
Lancet Oncol. 2026 Sep;27(9):1120-1132
https://pubmed.ncbi.nlm.nih.gov/42633754/
Results of intensifying radiation treatment in advanced laryngeal, hypopharyngeal (LH) and oropharyngeal cancers (OPC) using metabolic dose escalation strategies: (INTELHOPE)
Radiother Oncol. 2026 Sep;222:111698.
https://pubmed.ncbi.nlm.nih.gov/42435815/
Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial
Lancet Oncol. 2026 Jul;27(7):864-878.
https://pubmed.ncbi.nlm.nih.gov/42372746/
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer
J Clin Oncol. 2026 Sep 20;44(27):2574-2581.
https://pubmed.ncbi.nlm.nih.gov/42361282/
Dosimetric analysis of post-radiotherapy sexual dysfunction in patients receiving definitive stereotactic body radiotherapy (SBRT) for prostate cancer: a secondary analysis of MIRAGE
Radiother Oncol. 2026 Sep;222:111683.
https://pubmed.ncbi.nlm.nih.gov/42435817/
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Lancet. 2026 Sep 19;408(10560):1114-1128.
https://pubmed.ncbi.nlm.nih.gov/42716074/
Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial
Radiother Oncol. 2026 Sep;222:111672.
https://pubmed.ncbi.nlm.nih.gov/42364816/
Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial
J Clin Oncol. 2026 Sep;44(25):2409-2421.
https://pubmed.ncbi.nlm.nih.gov/42492015/
